340B Litigation and the Path Toward Transparent Drug Discount ProgramsByAngie Franks, KalderosAugust 13th 2025As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.